1Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin[J]. Kidney Int, 1996,50: 1694-1699.
2Mitsuiki K, Harada A, Miyata Y. Assessment of iron deficiency in chronic hemodialysis patients: Investigation of cutoff values for reticuloeyte hemoglobin content[J]. Clin Exp Nephrol, 2003,7:52-57.
3National Kidney Foundation:K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Diseasw[J]: update 2000. Am J Kidney Dis, 2001,37: s182-s238.
4Nissenson AR, Charytan C. Controversies in iron management [J]. Kidney Int, 2003, 64: s64-s71.
5Folkert VW, Michael B, AgarwalR, et al. Chronic use of sodium ferric gluconate complex in hemodialysis patients: Safety of higher dose(250mg) administration[J]. Am J Kidney Dis, 2003, 41: 551-657.
6Fletes R, Lazarus JM, Gage J, et al. Suspected iron dextran-related adverse drug events in hemodialysis patients [J]. Am J Kidney Dis, 2001, 37:743-749.
7Fishbane S, Ungeanu VD, Maesaka JK, et al. The safety of intravenous iron dextran in hemodialysis patients[J]. Am J Kidney Dis, 1996, 28: 529-534.
8Kosch M, Bahner U, Bettger H, et al. A randomized, controlled parallel group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate(Ferrleeit) in hemodialysis patients treated with rHuEPO[J]. Nephrol Dial Transplant, 2001. 16: 1239-1244.
9Sengolge G, Horl WH, Sunder Plassmann G. Intravenous iron therapy: well tolerated, yet not harmless[]]. Eur J Clin Invest, 2005, 35: 46-51.
